Why This Matters
The United States has been officially measles-free since 2000, a designation that reflects more than a quarter-century of sustained high vaccination rates and the public health infrastructure to contain any imported cases before they become outbreaks. That designation is now under formal review.
In November 2026, the Pan American Health Organization's Regional Verification Commission for the Elimination of Measles, Rubella, and Congenital Rubella Syndrome will formally evaluate whether the U.S. still meets the criteria for measles elimination. With 2,295 confirmed cases as of July 22, 34 new outbreaks recorded in 2026 alone, and genetic evidence of sustained domestic transmission stretching back to January 2025, independent experts say the evidence already satisfies the technical definition of endemic spread.
Losing elimination status would not mean measles is suddenly more dangerous to any individual American. But it would carry significant public health consequences that are worth understanding before the November verdict arrives.
What We Know So Far
PAHO formally announced on March 2, 2026, that the November review had been rescheduled from an earlier April session at the request of U.S. health officials, who cited the need for more time to complete genomic sequencing and comprehensive analysis of the 2025 outbreak data, according to CNN's reporting and the PAHO official statement.
The review will cover both the United States and Mexico, both of which have experienced major sustained outbreaks. The PAHO statement confirmed the review will apply established criteria to "those with active outbreaks and those that have completed one year of sustained transmission."
As of the CDC's July 16 update, 2,260 confirmed cases had been reported across 44 jurisdictions in 2026. The Johns Hopkins tracker, which pulls from state and local sources in real time, confirmed 2,295 cases as of July 22. Of CDC-confirmed cases, 93% were outbreak-associated, and 34 new outbreaks have been recorded in 2026.
Canada lost its measles elimination status in November 2025 after PAHO determined it had experienced more than 12 consecutive months of continuous domestic transmission. Canada recorded 5,463 measles cases in 2025. The Americas region as a whole reported 14,975 cases that year, with the overwhelming majority in North America.
Where the Risk Is Highest
Measles cases in 2026 are distributed across 44 jurisdictions, meaning no single region is isolated. But the concentration of cases reveals a consistent pattern. South Carolina leads with 670 confirmed cases, followed by Utah with 518 and Texas with 182. Each of those states contains communities, school districts, and religious communities where MMR vaccination coverage has fallen below the 95% threshold required to prevent sustained spread.
The American Association of State and Territorial Health Officials (ASTHO) notes that when elimination status holds, vulnerable populations, including infants too young to be vaccinated and immunocompromised individuals who cannot receive live vaccines, receive substantial indirect protection from a highly vaccinated surrounding population. When vaccination gaps allow ongoing transmission, that protection erodes.
According to KFF analysis, a higher percentage of cases since 2025 have resulted from local transmission rather than importation, a shift that is consistent with endemic spread and directly relevant to the PAHO determination.
What Doctors and Experts Say
Researchers at the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota published a pointed op-ed on June 24, 2026, calling on public health officials to stop hedging language and acknowledge what the data already make clear: that measles elimination is over in practice. The CIDRAP authors noted that genomic sequencing of the D8-9171 lineage circulating since at least January 2025 is consistent with unbroken domestic transmission, and that the PAHO review in November will formalize what the science has already established.
Dr. William Moss of the Johns Hopkins Bloomberg School of Public Health told the Washington Post earlier this week that the age breakdown of 2026 cases tells an important structural story. Roughly 20% of cases are in children under five, 50% in people aged 5 to 19, and 30% in adults 20 and older. "That tells us this has been years of undervaccination in some communities," Moss said. "This has been years in the making. It's not just the result of one outbreak."
The PAHO review process is technical and nuanced. KFF's analysis notes that the key question is not simply case counts but whether whole-genome sequencing can show uninterrupted domestic transmission for 12 or more consecutive months. The D8-9171 lineage has been the predominant genotype since the January 2025 Texas outbreak. Whether that constitutes a continuous transmission chain or a series of linked but technically separate events is the genomic determination the commission will evaluate.
What the Evidence Shows and What It Does Not
Measles elimination, as PAHO defines it, means the interruption of endemic measles virus transmission in a defined geographical area for more than 12 consecutive months. The key technical question is whether the large outbreaks of 2025 and 2026 represent a continuous domestic transmission chain or a series of separately introduced cases linked by the same circulating genotype.
Genomic sequencing of the circulating D8-9171 lineage is what distinguishes those two scenarios. The U.S. CDC and its partners have been conducting that sequencing. The results will be submitted to PAHO before the November commission meeting.
What the case data alone prove is that ongoing measles transmission at scale is occurring in the United States in 2026. What they do not prove, until genomic analysis confirms it, is whether that transmission has been uninterrupted from a single domestic chain going back 18-plus months.
MedicalDaily Evidence Check
- Data source: CDC confirmed case surveillance, July 16, 2026; Johns Hopkins U.S. Measles Tracker, July 22, 2026; PAHO official statement, March 2, 2026
- What it shows: 2,295 confirmed U.S. measles cases in 2026 with 34 new outbreaks; 93% outbreak-associated; PAHO review scheduled November 2026
- What it does not prove: That the U.S. will definitively lose elimination status; the genomic determination is still under analysis; PAHO has not yet ruled
-
What readers should know: The two-dose MMR vaccine remains highly effective for fully vaccinated individuals; the risk falls almost entirely on unvaccinated people; fully vaccinated people are well protected against measles
Who Faces the Greatest Risk?
People most vulnerable to measles and to the consequences of declining elimination status include:
- Unvaccinated or under-vaccinated children, who account for the overwhelming majority of outbreak-associated cases
- Infants younger than 12 months who are too young to receive MMR and depend on the immunity of those around them
- Pregnant women who lack documented immunity and face risks of miscarriage and premature birth from measles infection
- People with weakened immune systems who cannot receive live vaccines
-
Residents of communities where school-level MMR coverage falls below 95%
Symptoms and Warning Signs to Watch For
Measles symptoms begin seven to 14 days after exposure and include:
- High fever, sometimes reaching 104°F or higher
- Runny nose, cough, and red watery eyes
- Small white spots inside the mouth (Koplik's spots), appearing before the rash
- A red, blotchy rash beginning on the face and spreading downward
Anyone who develops these symptoms and believes they may have been exposed should call a health-care provider before visiting a clinic, to prevent spread in waiting rooms.
Measles can cause severe complications including pneumonia, encephalitis, and permanent hearing loss.
What You Can Do Now
- Verify your vaccination status and that of your children. Two doses of the MMR vaccine are needed for full protection. If you are unsure of your status, ask your physician or local health department.
- Parents planning international travel with children should consult a travel medicine physician, as early MMR doses starting at 6 months may be recommended for travel to affected regions.
- If you live in a community or state with high case counts, check with your local or county health department for current outbreak alerts.
-
If you have received two documented MMR doses, you are considered fully protected regardless of the PAHO status determination.
Cost and Access: What Patients Should Know
The MMR vaccine is available at no cost for children through the Vaccines for Children (VFC) program. For uninsured adults, the vaccine is available at reduced or no cost through federally qualified health centers and local health department clinics.
If you are unsure of your immunity status, a blood test called an MMR titer can confirm whether you have adequate measles antibodies. This test is covered by most insurance plans. If immunity is confirmed, no additional vaccination is needed.
What Happens Next
The PAHO Regional Verification Commission is expected to meet in November 2026. The commission will review genomic sequencing data, epidemiological reports, and public health response documentation submitted by U.S. health authorities. A formal determination on U.S. measles elimination status will follow.
If the U.S. loses elimination status, it would not trigger any immediate change in CDC guidance on vaccination. The practical effect would be reputational and diplomatic: the U.S. would join Canada as the second North American country to lose a designation it has held since the early 2000s, and the finding would add pressure on policymakers to address the vaccination coverage gaps driving transmission.
MedicalDaily will continue covering measles case data and will report directly from the November PAHO review.
The Bottom Line
The United States is approaching a formal international review of whether it still qualifies as measles-free, a status held since 2000. With 2,295 confirmed cases, 34 active outbreaks, and a sustained circulating measles lineage dating back to January 2025, the data are consistent with what public health experts define as endemic spread. Whether the November PAHO review results in a formal change to U.S. status depends on the genomic sequencing evidence. What the data already make clear is that sustained under-vaccination in specific communities has allowed measles to regain a foothold in the United States that will take years to reverse.
